Is It Time To Reassess Neurocrine Biosciences (NBIX) After Its Recent Share Price Pullback? [Yahoo! Finance]
Neurocrine Biosciences, Inc. (NBIX)
Last neurocrine biosciences, inc. earnings: 2/4 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
neurocrine.com/about-us/webcasts-presentations
Company Research
Source: Yahoo! Finance
If you are wondering whether Neurocrine Biosciences at around US$128 per share is still priced sensibly or already stretching expectations, the valuation story is where things get interesting. The stock has seen mixed returns recently, with a 2.5% decline over the last week and a 1.8% decline over the past month, but it still shows 26.7% over 1 year, 22.8% over 3 years, and 33.1% over 5 years. Recent attention on Neurocrine Biosciences has focused on its position in the pharmaceuticals and biotech space and how the market is reacting to its ongoing product and pipeline developments. This context helps explain why the share price can shift even when there is no single headline driving sentiment. On Simply Wall St's valuation checks, Neurocrine Biosciences currently scores 3 out of 6 . The next step is to break down how different valuation methods assess the stock today, and then look at a more complete way to think about value at the end of this article. Find out why Neurocrin
Show less
Read more
Impact Snapshot
Event Time:
NBIX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NBIX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NBIX alerts
High impacting Neurocrine Biosciences, Inc. news events
Weekly update
A roundup of the hottest topics
NBIX
News
- Neurocrine Biosciences (NBIX) was upgraded by Zacks Research from "strong sell" to "hold".MarketBeat
- How Investors May Respond To Neurocrine Biosciences (NBIX) INGREZZA Real-World Persistence Edge Over AUSTEDO XR [Yahoo! Finance]Yahoo! Finance
- Neurocrine Biosciences Announces Conference Call and Webcast of First Quarter 2026 Financial Results [Yahoo! Finance]Yahoo! Finance
- Neurocrine Biosciences Announces Conference Call and Webcast of First Quarter 2026 Financial Results [TheStreet.com]TheStreet.com
- Neurocrine Biosciences Announces Conference Call and Webcast of First Quarter 2026 Financial ResultsPR Newswire
NBIX
Earnings
- 2/11/26 - Beat
NBIX
Sec Filings
- 4/15/26 - Form DEFA14A
- 4/15/26 - Form ARS
- 4/15/26 - Form DEF
- NBIX's page on the SEC website